安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Genentech: Rozlytrek® (entrectinib) - Information for Patients
What is ROZLYTREK ® (entrectinib)? ROZLYTREK is a prescription medicine used to treat: Adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene
- FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC
On August 15, 2019, the Food and Drug Administration granted accelerated approval to entrectinib (ROZLYTREK, Genentech Inc ) for adults and pediatric patients 12 years of age and older with solid
- Entrectinib (oral route) - Mayo Clinic
Entrectinib is used to treat metastatic (lung cancer that has already spread) non-small cell lung cancer (NSCLC) that is caused by a gene called ROS1
- Entrectinib Uses, Side Effects Warnings - Drugs. com
What is entrectinib? Entrectinib is used in adults to treat non-small cell lung cancer that has spread to other parts of the body (metastatic)
- Entrectinib - NCI - National Cancer Institute
Entrectinib is approved to treat: Non-small cell lung cancer that is ROS1 positive It is used in adults whose cancer has spread to other parts of the body Solid tumors that have an NTRK gene fusion without a drug-resistance mutation in certain TRK proteins
- Entrectinib (Rozlytrek) - NCBI Bookshelf
Entrectinib is an inhibitor of tyrosine receptor kinases A, B, and C (TRKA, TRKB, and TRKC) (encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively), proto-oncogene tyrosine-protein kinase ROS (ROS1; encoded by the gene ROS1), and anaplastic lymphoma kinase (ALK; encoded by the gene ALK)
- Entrectinib: Uses, Interactions, Mechanism of Action - DrugBank Online
Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor 7 It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors 9
- Entrectinib (Rozlytrek®) - Macmillan Cancer Support
Entrectinib belongs to a group of targeted therapy drugs called tyrosine kinase inhibitors (TKIs) It is used to treat cancers that have a change in genes called NTRK It is also used to treat non-small cell lung cancer (NSCLC)
|
|
|